Madrigal Pharmaceuticals(US:MDGL)2025-11-04 13:00Rezdiffra Sales Performance - Rezdiffra's net sales for 3Q25 reached $287.3 million[13], annualizing at over $1 billion[9, 13] - From 2Q25 to 3Q25, Rezdiffra experienced a quarter-over-quarter growth of 35%[13] - Over 29,500 patients are currently on Rezdiffra[9, 16] - More than 10,000 healthcare providers have prescribed Rezdiffra to date[9, 19] Market and Pipeline Expansion - Madrigal is advancing Rezdiffra in a compensated MASH cirrhosis (F4c) trial, aiming to be first to market[11] - The company completed the transaction of oral GLP-1 (MGL-2086)[11] - Data from the MAESTRO-NASH OUTCOMES trial (F4c) is expected in 2027[37], and MAESTRO-NASH (F2/F3) data is expected in 2028[37] - MGL-2086/resmetirom combo is expected to enter clinic in the first half of 2026[37] - Rezdiffra has broad first-line access with no step edit requirements and improvements in utilization management criteria[31] Financial Position - Madrigal reported $1.1 billion in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2025[46] - Net product revenue for 3Q25 was $287.268 million, compared to $62.175 million in 3Q24[44] - The net loss for 3Q25 was ($114.190) million, compared to ($106.964) million in 3Q24[44]